KIT, NRAS and BRAF mutations in head and neck (upper aerodigestive tract) mucosal melanoma (a study of 21 cases)
https://doi.org/10.17650/2222-1468-2017-7-1-69-74
Abstract
Objective. Determination of mutation rates in KIT, NRAS and BRAF genes in 21 samples of mucosal melanoma of the upper aerodigеstive tract.
Background. Head and neck mucosal melanomas (or upper aerodigestive tract mucosal melanomas) are rare and aggressive tumors of melanocytic origin. Head and neck mucosal melanoma (HNMM) comprises over 50 % of all mucosal melanomas. The aim was to determine the KIT, NRAS and BRAF mutation frequencies in 21 series of primary HNMM.
Methods. Microdissected tumour cells were used from 21 formalin-fixed paraffin-embedded tumours. The tumour cells were screened for KIT, NRAS and BRAF mutations by direct sequencing.
Results. Overall, 19 % (4 out of 21) of HNMMs harboured KIT, NRAS or BRAF mutations. Mutations in these oncogenes occurred in a mutuаlly exclusive manner. Both NRAS and BRAF mutations were identified at a similar frequency of 4,75 % each (1 and 1 out of 21), whereas KIT mutations were detected in 9,5 % (2 out of 21) of the HNMMs. KIT mutations were located in exon 11.
Conclusion. Our findings shоw that NRAS and BRAF mutations, which are aсcessible for present targeted thеrapies, are only rarеly present in HNMMs, whereas KIT mutations seem to be relatively more frequent.
About the Authors
A. V. Ignatova
Russian Medical Academy of Continuous Professional Education at the Ministry of Health of Russia
Russian Federation
2/1 Barrikadnaya St., Moscow 123993, Russia
Russian Federation
2/1 Barrikadnaya St., Moscow 123993, Russia
A. M. Stroganova
Research Institute of Clinical Oncology of N.N. Blokhin Russian Cancer Research Center at the Ministry of Health of Russia
Russian Federation
23 Kashirskoe Sh., Moscow 115478, Russia
Russian Federation
23 Kashirskoe Sh., Moscow 115478, Russia
S. L. Dranko
Research Institute of Clinical Oncology of N.N. Blokhin Russian Cancer Research Center at the Ministry of Health of Russia
Russian Federation
23 Kashirskoe Sh., Moscow 115478, Russia
Russian Federation
23 Kashirskoe Sh., Moscow 115478, Russia
A. I. Senderovich
Research Institute of Clinical Oncology of N.N. Blokhin Russian Cancer Research Center at the Ministry of Health of Russia
Russian Federation
23 Kashirskoe Sh., Moscow 115478, Russia
Russian Federation
23 Kashirskoe Sh., Moscow 115478, Russia
S. O. Podvyaznikov
Russian Medical Academy of Continuous Professional Education at the Ministry of Health of Russia
Russian Federation
2/1 Barrikadnaya St., Moscow 123993, Russia
Russian Federation
2/1 Barrikadnaya St., Moscow 123993, Russia
References
1. Weber C.O. Surgical experience and research, in addition to interesting observations from the Surgical Clinic and the Protestant Hospital Bonn. Berlin, Germany: G. Reimer, 1859. Р. 304–5.
2. Manolidis S., Donald P.J. Malignant mucosal melanoma of the head and neck: review of the literature and report of 14 patients. Cancer 1997;80:1373–86. PMID: 9338460.
3. Lourenço S.V., Sangueza M., Sotto M.N. et al. Primary oral mucosal melanoma: a series of 35 new cases from South America. Am J Dermatopathol 2009;31:323–30. DOI: 10.1097/DAD.0b013e3181a0d37c. PMID: 19461235.
4. Anderson L.J., Berthelsen A., Hansen H.S. Malignant melanoma of the upper respiratory tract and the oral cavity. J Otolaryngol 1992;21:180–5.
5. Thompson L.D., Wieneke J.A., Miettinen M. Sinonasal tract and nasopharyngeal melanomas: a clinicopathologic study of 115 cases with a proposed staging system. Am J Surg Pathol 2003;27:594–611. PMID: 12717245.
6. Patel S.G., Prasad M.L., Escrig M. Primary mucosal malignant melanoma of the head and neck. Head Neck 2002;24:247–57. PMID: 11891956.
7. Owens J.M., Roberts D.B., Myers J.N. The role of postoperative adjuvantradiation therapy in the treatment of mucosal melanomas of the head and neck region. Arch Otolaryngol Head Neck Surg 2003;129:864–8. DOI: 10.1001/archotol.129.8.864. PMID: 12925346.
8. Gorsky M., Epstein J.B. Melanoma arising from the mucosal surfaces of the head and neck. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;86:715–9. PMID: 9868730.
9. Trap T.K., Fu Y., Calcaterra T.C. Melanoma of the nasal and paranasal sinus mucosa. Arch Otolaryngol Head Neck Surg 1987;113(10):1086– 9. PMID: 3620131.
10. Papaspyrou G., Garbe C., Schadendorf D. et al. Mucosal melanomas of the head and neck: new aspects of the clinical outcome, molecular pathology, and treatment with c-kit inhibitors. Melanoma Res 2011;21: 475–82. DOI: 10.1097/CMR.0b013e32834b58cf. PMID: 21897303.
11. Davies H., Bignell G.R., Cox C. et al. Mutations of the BRAF gene in human cancer. Nature 2002;417(6892):949–54. DOI: 10.1038/nature00766. PMID: 12068308.
12. Omholt K., Grafström E., Kanter-Lewensohn L. et al. KIT pathway alterations in mucosal melanomas of the vulva and other sites. Clin Cancer Res 2011;17:3933–42. DOI: 10.1158/1078-0432.CCR-10-2917. PMID: 21680547.
13. Carvajal R.D., Spencer S.A., Lydiatt W. Mucosal melanoma: a clinically and biologically unique disease entity. J Natl Compr Cancer Netw 2012;10(3):345–56. PMID: 22393195.
14. Turri-Zanoni M., Medicina D., Lombar - di D. et al. Sinonasal mucosal melanoma: molecular profile and therapeutic implications from a series of 32 cases. Head Neck 2013;35:1066–77. DOI: 10.1002/hed.23079. PMID: 22791410.
15. Ascierto P.A., Minor D., Ribas A. et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 2013;31(26):3205–11. DOI: 10.1200/JCO.2013.49.8691. PMID: 23918947.
16. Chapman P.B., Hauschild A., Robert C. et al. (BRIM-3 Study Group.). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364(26):2507–16. DOI: 10.1056/NEJMoa1103782. PMID: 21639808.
17. Zebary A., Jangard M., Omholt K. et al. KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases: British Journal of Cancer 2013;109:559–64. DOI: 10.1038/bjc.2013.373. PMID: 23860532.
18. Gorden A., Osman I., Gai W. et al. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer research 2003;63(14):3955–7. PMID: 12873990.
19. Wilson M.A., Zhao F., Letrero R. et al. Correlation of somatic mutations and clini cal outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib. Clin Cancer Res 2014;20(12):3328–37. DOI: 10.1158/1078-0432.CCR-14-0093. PMID: 24714776.
20. Beadling C., Jacobson-Dunlop E., Hodi F.S. et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008;14:6821–8. DOI: 10.1158/1078-0432.CCR-08- 0575. PMID: 18980976.
21. Schoenewolf N.L., Bull C., Belloni B. et al. Sinonasal, genital and acrolentiginous melanomas show distinct characteristics of KIT expression and mutations. Eur J Cancer 2012;48: 1842–52. DOI: 10.1016/j.ejca.2012.02.049. PMID: 22464346.
Review
For citations:
Ignatova A.V., Stroganova A.M., Dranko S.L., Senderovich A.I., Podvyaznikov S.O. KIT, NRAS and BRAF mutations in head and neck (upper aerodigestive tract) mucosal melanoma (a study of 21 cases). Head and Neck Tumors (HNT). 2017;7(1):69-74. (In Russ.) https://doi.org/10.17650/2222-1468-2017-7-1-69-74
Views:
5711
Email this article 